SUMMARY Myocardial ischemic injury after temporary occlusion of the left anterior descending coronary artery (LAD) for 90 min followed by reperfusion was estimated from the epicardial STsegment elevation 15 min after occlusion (STi5m,), changes in QRS complex, myocardial creatine kinase (CPK) activity and nitro-bluetetrazolium (NBT) staining at 24 hours. At all sites exhibiting STi5m greater than 2 mV, there was a small development of epicardial Q waves after 90 min of occlusion (I AQ = 0.74 ± 0.11 mV) which was enhanced during reperfusion, reaching a maximum at 60 min (2 AQ = 6.94 + 0.52 mV) and was maintained for 24 hours. Good correlations were obtained between CPK activity at 24 hours and the CARDIAC FAILURE remains the major cause of death among patients who have experienced an acute myocardial infarction. Considerable effort has been made in the past several years to devise pharmacologic approaches to protecting the ischemic heart with the hope of minimizing the ultimate extent of myocardial damage. Several pharmacologic and metabolic interventions have been reported to exert a beneficial effect in reducing the amount of cardiac tissue that would otherwise undergo irreversible damage due to myocardial ischemia.1
development of Q waves at 24 hours as well as at 60 min after reperfusion (r = 0.49; N = 56). Pretreatment with UM-272 significantly reduced the development of Q-waves (Z AQlh. = 2.23 ± 0.75 mV) which was correlated with less CPK depletion and smaller infarct size as determined on the basis of NBT staining for myocardial tissue dehydrogenases at 24 hours.
It appears, therefore, that the assessment of pathologic Q wave development provides an accurate and early estimate of the extent of the ultimate cardiac damage due to ischemia and that pretreatment with UM-272 exerts a protective effect on the ischemic myocardium.
with determinations of myocardial CPK activity and direct gravimetric analysis of infarct size.
The results of the present study support our previous observations5 regarding the ability of UM-272 to protect the ischemic myocardium from irreversible injury, and in addition, demonstrate that pretreatment with significantly reduced the development of pathologic Q waves from potentially ischemic regions of the ventricle and significantly reduced the loss of myocardial CPK from the ischemic tissues.
Methods Animal Preparation
Male, mongrel dogs weighing between 16 .1 to 22.0 kg (mean of 18.6 kg) were anesthetized with pentobarbital sodium (30 mg/kg) i.v. Each dog was intubated with a cuffed endotracheal tube and ventilated with room air using a Harvard respirator. Sterile catheters were implanted in the left carotid artery and jugular vein and were brought to the surface of the skin at the back of the neck. Arterial blood pressure was monitored using a Statham P23DC pressure transducer connected to the carotid catheter. The jugular vein catheter was used for all subsequent drug administrations. Electrocardiograms from limb leads II and aVF were recorded on a Grass model 7 polygraph.
A lateral thoracotomy was performed through the fifth left intercostal space and the heart suspended in a pericardial cradle. The left anterior descending coronary artery (LAD) was isolated below its first diagonal branch and, at the appropriate time, the blood flow was interrupted with a screw clamp ( fig. 1 ). After 90 min of LAD occlusion, the blood flow was reinstituted over 20 min in an incremental fashion in which 25% of the preischemic flow was reinstituted at 0 time (i.e., after 90 min of occlusion), another 25% after 10 min and then the LAD was released completely after 20 min. An electromagnetic flow probe was used to continuously monitor LAD flow. The gradual reinstitution of coronary flow minimized the development of a reactive hyperemic response and thus reduced the incidence of hemorrhagic infarction and ventricular fibrillation. 5 Epicardial electrograms were recorded with 12 platinum electrodes embedded in a 3 X 4 cm acrylic plaque (Perm, The Hygienic Dental Co.) in such a manner that the electrodes were 1 cm apart. (5) and 11 (1) , suggesting that the dysrhythmias appear to originate from multifocal ectopic sites.12 Pretreatment with UM-272 (2 mg/kg), 30 min prior to LAD occlusion, resulted in a slight decrease in heart rate (-7.4 2.4%) and no change in mean arterial blood pressure. The subsequent decrease in blood pressure 24 hours after LAD occlusion was not significantly different between UM-272-treated and saline-treated animals. UM-272 treatment, however, did appear to reduce markedly the severity of ventricular dysrhythmias at 24 hours. In the UM-272 pretreated animals, the ventricular dysrhythmias monitored over a one hour period were graded primarily as 11 (5) and III (I) according to Lown's classification,'2 indicating that unifocal ectopic rhythms were predominant in the drugtreated animals.
Despite a gradual re-introduction of coronary flow into the ischemic region after a 90 min period of coronary occlusion, patchy hemorrhagic infarction was observed to occur in five out of seven control and one out of six UM-272 pret'reated animals. A minimum of eight transmural specimens from the available 12 electrodes was used for the FIGURE 2 . Typical tracings of the epicardial electrocardiographic changes during coronary occlusion and reperfusion in the control and drugtreated dogs. In both groups, the left anterior descending coronary artery (LAD) was occluded below its first diagonal branch. Following 90 min of occlusion the blood flow was re-instituted over 20 min in an incremental fashion to minimize hemorrhagic infarct and ventricular fibrillation. subsequent studies, thus eliminating those areas that exhibited hemorrhagic infarction.
Electrocardiographic Studies Figure 2 shows a typical tracing of the epicardial electrocardiographic changes during 90 min of LAD occlusion followed by reperfusion in the control and drug-treated animals. In both groups, there was an increase in STsegment elevation after coronary occlusion which declined gradually thereafter. The decline was more marked upon reperfusion of the ischemic region. In the control animals, there was a small development of Q waves after 90 min of coronary occlusion and their appearance was greatly enhanced during reperfusion. In the UM-272-treated animals, however, despite a similar increase in ST-segment elevation 15 min after LAD occlusion, the subsequent development of Q waves was significantly less than in the control animals. 24 hours later ( fig. 3 ).
Discussion
Recently it has been reported5 that pretreatment with UM-272, the quaternary analog of propranolol, significantly reduced the amount of myocardial tissue undergoing irreversible ischemic injury when canine hearts were subjected to 60 min of occlusion of the left circumflex coronary artery (LCX). In addition, treated animals were noted to have a decrease in the incidence of rhythm disturbances during LCX occlusion and after reperfusion. The present study has employed alterations in R and Q wave voltages as a means of assessing myocardial injury and cell death. The results provide further evidence that pretreatment with UM-272 affords protection against myocardial cell injury caused by temporary myocardial ischemia. In addition, two independent quantitative measurements of infarct size were FIGURE 6. The time course for the development of epicardial Q waves during 90 min of LAD occlusion and reperfusion. The development of epicardial Q waves was monitored at all the epicardial electrode sites exhibiting ST-segment elevation greater than 2 mV 15 min after LAD occlusion. In both groups, the appearance of Q waves was minimal during the 90 min ofocclusion and was enhanced during reperfusion. In the six UM-272 treated dogs, despite a similar increase in STi,m, the subsequent development of Q waves was significantly less than that observed in the seven controls at all time points monitored. 545 VOL 57, No 3, MARCH 1978 used in the present study. One method involved the determination of myocardial CPK activity in nonischemic and ischemic myocardial regions and the other depended upon the presence of intracellular dehydrogenase enzymes and substrate and their reaction with NBT." Each of these estimates of cell viability provided further evidence that pretreatment with UM-272 protected ischemic myocardium from irreversible cell injury and death. These observations support those of a previous study in which occlusion of the LCX for 60 min followed by reperfusion for 24 hours resulted in an infarct volume of 23.8 ± 3.2% of the left ventricle as compared to animals pretreated with UM-272 (12.5 mg/kg over 5 hours) in which the infarct volume was 7.0 ± 3.3 percent. 5 The observations in the present study in which the LAD was occluded for 90 min resulted in an infarct volume of 24.2 ± 2.8% in controls vs. 6.6 ± 3.7% in UM-272 treated dogs are in excellent agreement with our earlier investigations showing that UM-272 can protect the ischemic myocardium against permanent cell injury and ultimate necrosis.
Although pretreatment with UM-272 did not prevent ventricular arrhythmias from occurring at 24 hours after temporary LAD occlusion and reperfusion, it reduced the severity of these arrhythmias as quantitated according to the method of Lown et al.12 It has been reported recently that there are limitations to Lown's classification,13 but the marked differences in frequency and pattern of ventricular dysrhythmias between the saline controls and UM-272 treated animals in the present study clearly indicated an antiarrhythmic property of UM-272. In the UM-272 treated animals, ventricular arrhythmias were characterized by electrocardiographic patterns suggesting that they were of unifocal origin as compared to untreated animals in which the arrhythmias were graded as being more severe in character in that they were multifocal. This observation may be of clinical significance in view of the recent observations of Lown and Grayboys"4 in which it was noted that one of the therapeutic objectives for the management of malignant arrhythmias and the prevention of sudden death was to suppress the more severe grades (grades 4 and 5) of ventricular arrhythmias. The results of the present study support earlier observations5 in which UM-272 produced a marked reduction in ventricular ectopic activity noted to occur within the first 5 hours after a 60 min period of LCX occlusion followed by reperfusion in the canine heart. Whereas UM-272 pretreatment did not produce significant effects upon epicardial ST-segment elevations measured at 15 min after LAD occlusion, the drug produced a significant reduction in the development of pathologic Q waves recorded from these same sites at 24 hours and reduced the loss of myocardial CPK from tissue specimens taken at the same electrode sites.
A number of intracellular enzyme markers have been used to quantify the amount of myocardial tissue undergoing irreversible cell injury or necrosis.'5"'l In recent years, depletion of creatine kinase (CPK) from myocardial tissue has been employed as an estimate of myocardial cell death after coronary artery occlusion.' 16, 17, 19 An extremely useful method for experimental studies is that of Nachlas and Shnitka"l which involves the use of nitro-blue-tetrazolium (NBT) which stains myocardial tissue a deep blue color in could reduce the mass of ventricular myocardium undergoing irreversible damage as a result of ischemia followed by reperfusion. The present studies provide additional evidence for the protective effects of UM-272 by demonstrating that CPK activity of the previous ischemic region is preserved and pathologic Q wave development is not as marked in the presence of drug treatment as compared to saline-treated controls.
The present study adds further evidence to support the concept that pharmacologic interventions might save the jeopardized, but still viable ischemic myocardial cells. The mechanism by which UM-272 protects the ischemic heart is not addressed in this present study. Previous studies, however, have demonstrated that UM-272 has the ability to reduce myocardial oxygen consumption27"29 by reducing myocardial oxygen demands and these changes were associated with a reduction in coronary blood flow. The reduction in myocardial oxygen demand was related to a decrease in heart rate and contractility, resulting in a decrease in cardiac output and tension-time index. The decrease in contractility alone was sufficiently pronounced to decrease myocardial oxygen demands since myocardial oxygen consumption remained below the control value even when heart rate and blood pressure were restored to at least control levels by electrical pacing and aortic obstruction. Thus, it is reasonable to assume that UM-272 might bring about a more favorable balance between oxygen supply and oxygen demand particularly in the postocclusive period when the "no-reflow" phenomenon may result in limited flow to large areas of the myocardium so as to render them relatively ischemic for a variable time period following reperfusion. In the absence of drug treatment, such areas of relative ischemia would be in jeopardy and subjected to the dynamic processes leading to irreversible cell injury and ultimate cell death and necrosis. Whereas UM-272 may not alter the changes that occur within the microcirculation and some degree of ischemia may persist beyond the time of reperfusion, the ability of the drug to reduce myocardial oxygen demands may account for its protective effect upon the jeopardized myocardial cells. Still another mechanism by which one could explain the protective effects of UM-272 upon the ischemic heart is provided by the data of Warltier et al. 30 and Gross et al. 3 ' who showed that the drug produced a redistribution of coronary blood flow from epicardial to endocardial regions in hearts subjected to a critical stenosis of the LAD. This latter effect together with a reduction in myocardial oxygen consumption would be sufficient to explain the beneficial effects of dimethyl propranolol upon the ischemic myocardium that would result in a reduction in the volume of ventricular muscle undergoing necrosis, the preservation of myocardial CPK activity, and the prevention of pathologic Q wave development.
From a clinical standpoint, the need to preserve jeopardized, but still viable myocardial tissue, is evident in view of the fact that the degree of morbidity and mortality subsequent to myocardial infarction are related to the amount of myocardial tissue undergoing irreversible damage. The dimethyl-quaternary analog of propranolol, UM-272, which lacks beta-adrenergic receptor blocking properties, should provide an interesting potential therapeutic intervention for the purpose of reducing infarct size. The studies with UM-272 to date5' 28-31 suggest it possesses all of the beneficial properties of propranolol with respect to restoring the balance between oxygen supply and oxygen demand in the ischemic heart. In addition, UM-272 brings about a favorable improvement in the endocardial-epicardial blood flow ratio in the ischemic heart. Thus, UM-272, like propranolol, might be of value clinically in preventing the extension of ischemic injury in patients with acute myocardial infarction. would have a therapeutic advantage over propranolol in that it would not produce betareceptor blockade and thus deprive the heart of needed inotropic and chronotropic support via the autonomic nervous system. Furthermore, the ability of UM-272 to protect the ischemic heart during the period of reperfusion might suggest a potential use of the drug in patients with unstable angina undergoing coronary bypass vein graft surgery in whom the rate of perioperative infarction associated with the appearance of new significant Q waves may be as high as 15%132 and may be associated with the reflow of arterial blood to a previously ischemic region.33
